Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.

Steele CD, Tarabichi M, Oukrif D, Webster AP, Ye H, Fittall M, Lombard P, Martincorena I, Tarpey PS, Collord G, Haase K, Strauss SJ, Berisha F, Vaikkinen H, Dhami P, Jansen M, Behjati S, Amary MF, Tirabosco R, Feber A, Campbell PJ, Alexandrov LB, Van Loo P, Flanagan AM, Pillay N.

Cancer Cell. 2019 Mar 18;35(3):441-456.e8. doi: 10.1016/j.ccell.2019.02.002.

2.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

3.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

4.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

5.

Current questions in bone sarcomas.

Strauss SJ, Whelan JS.

Curr Opin Oncol. 2018 Jul;30(4):252-259. doi: 10.1097/CCO.0000000000000456. Review.

PMID:
29782347
6.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823. No abstract available.

7.

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A.

Lancet Respir Med. 2018 Jun;6(6):431-441. doi: 10.1016/S2213-2600(18)30116-4. Epub 2018 Apr 15.

PMID:
29669701
8.

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ.

Eur J Cancer. 2018 May;94:156-167. doi: 10.1016/j.ejca.2018.02.011. Epub 2018 Mar 20.

PMID:
29567632
9.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527. Erratum in: Ann Oncol. 2019 Feb 1;30(2):344. Ann Oncol. 2019 Feb;30(2):344.

10.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

11.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS.

Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25.

12.

Follow-up practices for high-grade extremity Osteosarcoma.

Rothermundt C, Seddon BM, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Whelan JS.

BMC Cancer. 2016 May 6;16:301. doi: 10.1186/s12885-016-2333-y.

13.

EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.

Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Möller P, Brüderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM.

J Pathol. 2016 Jul;239(3):320-34. doi: 10.1002/path.4729. Epub 2016 May 31.

14.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3.

15.

Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.

Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H.

Cancer Res. 2014 Nov 15;74(22):6578-88. doi: 10.1158/0008-5472.CAN-14-1736. Epub 2014 Oct 3.

16.

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.

Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, Frezza AM, Behjati S, Tarpey P, Pillay N, Campbell PJ, Tirabosco R, Presneau N, Strauss SJ, Flanagan AM.

Cancer Med. 2014 Aug;3(4):980-7. doi: 10.1002/cam4.268. Epub 2014 May 27.

17.

What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.

Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM.

Br J Cancer. 2014 May 13;110(10):2420-6. doi: 10.1038/bjc.2014.200. Epub 2014 Apr 15.

18.

Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?

Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ.

BMC Cancer. 2014 Jan 15;14:23. doi: 10.1186/1471-2407-14-23.

19.

ERBB4 confers metastatic capacity in Ewing sarcoma.

Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH.

EMBO Mol Med. 2013 Jul;5(7):1087-102. doi: 10.1002/emmm.201202343. Epub 2013 May 16.

20.

A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines.

Lombardo CM, Welsh SJ, Strauss SJ, Dale AG, Todd AK, Nanjunda R, Wilson WD, Neidle S.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5984-8. doi: 10.1016/j.bmcl.2012.07.009. Epub 2012 Jul 14.

PMID:
22889802
21.

Management of the patient with neutropenic sepsis.

Welsh SJ, Strauss SJ.

Br J Hosp Med (Lond). 2012 Jul;73(7):C101-3. Review. No abstract available.

PMID:
22875396
22.

Assessment of the patient with neutropenic sepsis.

Welsh SJ, Strauss SJ.

Br J Hosp Med (Lond). 2012 Jun;73(6):C89-92. No abstract available.

PMID:
22875275
23.

Incidence and survival of malignant bone sarcomas in England 1979-2007.

Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, Strauss SJ.

Int J Cancer. 2012 Aug 15;131(4):E508-17. doi: 10.1002/ijc.26426. Epub 2011 Nov 2.

24.

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.

Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS.

Cancer. 2012 Apr 1;118(7):1856-67. doi: 10.1002/cncr.26472. Epub 2011 Sep 1.

25.

Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.

Strauss SJ, Ng T, Mendoza-Naranjo A, Whelan J, Sorensen PH.

Oncologist. 2010;15(6):627-35. doi: 10.1634/theoncologist.2010-0093. Epub 2010 May 17. Review.

26.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T.

Br J Cancer. 2010 Mar 30;102(7):1106-12. doi: 10.1038/sj.bjc.6605618. Epub 2010 Mar 16.

27.

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.

28.

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.

Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.

J Clin Oncol. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24.

PMID:
16864854
29.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA.

J Clin Oncol. 2006 May 1;24(13):2105-12. Epub 2006 Apr 10.

PMID:
16606971
30.

Late relapse of osteosarcoma: implications for follow-up and screening.

Strauss SJ, McTiernan A, Whelan JS.

Pediatr Blood Cancer. 2004 Nov;43(6):692-7.

PMID:
15390283
31.

s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.

Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, Joel SP, Malpas JS.

Hematol J. 2004;5(3):247-54.

PMID:
15167912
32.

A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.

Strauss SJ, Marples M, Napier MP, Meyer T, Boxall J, Rustin GJ.

Br J Cancer. 2003 Nov 17;89(10):1901-5.

33.

Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.

Strauss SJ, McTiernan A, Driver D, Hall-Craggs M, Sandison A, Cassoni AM, Kilby A, Michelagnoli M, Pringle J, Cobb J, Briggs T, Cannon S, Witt J, Whelan JS.

J Clin Oncol. 2003 Aug 1;21(15):2974-81.

PMID:
12885818

Supplemental Content

Loading ...
Support Center